145 related articles for article (PubMed ID: 38273849)
21. Radiological features and outcomes of combined hepatocellular-cholangiocarcinoma in patients undergoing surgical resection.
Chi CT; Chau GY; Lee RC; Chen YY; Lei HJ; Hou MC; Chao Y; Huang YH
J Formos Med Assoc; 2020 Jan; 119(1 Pt 1):125-133. PubMed ID: 30876788
[TBL] [Abstract][Full Text] [Related]
22. MRI features of combined hepatocellular- cholangiocarcinoma versus mass forming intrahepatic cholangiocarcinoma.
Sammon J; Fischer S; Menezes R; Hosseini-Nik H; Lewis S; Taouli B; Jhaveri K
Cancer Imaging; 2018 Feb; 18(1):8. PubMed ID: 29486800
[TBL] [Abstract][Full Text] [Related]
23. Integrated Genomic and Transcriptomic Analysis reveals key genes for predicting dual-phenotype Hepatocellular Carcinoma Prognosis.
Wang Y; Wang X; Huang X; Zhang J; Hu J; Qi Y; Xiang B; Wang Q
J Cancer; 2021; 12(10):2993-3010. PubMed ID: 33854600
[TBL] [Abstract][Full Text] [Related]
24. Clinical and pathological features of combined hepatocellular-cholangiocarcinoma compared with other liver cancers.
Wakizaka K; Yokoo H; Kamiyama T; Ohira M; Kato K; Fujii Y; Sugiyama K; Okada N; Ohata T; Nagatsu A; Shimada S; Orimo T; Kamachi H; Taketomi A
J Gastroenterol Hepatol; 2019 Jun; 34(6):1074-1080. PubMed ID: 30462849
[TBL] [Abstract][Full Text] [Related]
25. MRI features predict microvascular invasion in intrahepatic cholangiocarcinoma.
Ma X; Liu L; Fang J; Rao S; Lv L; Zeng M; Shi Y; Yang C
Cancer Imaging; 2020 Jun; 20(1):40. PubMed ID: 32576283
[TBL] [Abstract][Full Text] [Related]
26. Added value of ancillary imaging features for differentiating scirrhous hepatocellular carcinoma from intrahepatic cholangiocarcinoma on gadoxetic acid-enhanced MR imaging.
Choi SY; Kim YK; Min JH; Kang TW; Jeong WK; Ahn S; Won H
Eur Radiol; 2018 Jun; 28(6):2549-2560. PubMed ID: 29335868
[TBL] [Abstract][Full Text] [Related]
27. Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using gadoxetic acid-enhanced MRI.
Chong YS; Kim YK; Lee MW; Kim SH; Lee WJ; Rhim HC; Lee SJ
Clin Radiol; 2012 Aug; 67(8):766-73. PubMed ID: 22425613
[TBL] [Abstract][Full Text] [Related]
28. Distinguishing intrahepatic mass-forming biliary carcinomas from hepatocellular carcinoma by computed tomography and magnetic resonance imaging using the Bayesian method: a bi-center study.
Ichikawa S; Isoda H; Shimizu T; Tamada D; Taura K; Togashi K; Onishi H; Motosugi U
Eur Radiol; 2020 Nov; 30(11):5992-6002. PubMed ID: 32500195
[TBL] [Abstract][Full Text] [Related]
29. Different MR features for differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma according to tumor size.
Ni T; Shang XS; Wang WT; Hu XX; Zeng MS; Rao SX
Br J Radiol; 2018 Jul; 91(1088):20180017. PubMed ID: 29791202
[TBL] [Abstract][Full Text] [Related]
30. Differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma on gadoxetic acid-enhanced liver MR imaging.
Kim R; Lee JM; Shin CI; Lee ES; Yoon JH; Joo I; Kim SH; Hwang I; Han JK; Choi BI
Eur Radiol; 2016 Jun; 26(6):1808-17. PubMed ID: 26373763
[TBL] [Abstract][Full Text] [Related]
31. Enhancement Patterns of Intrahepatic Cholangiocarcinoma on Contrast-Enhanced Ultrasound: Correlation with Clinicopathologic Findings and Prognosis.
Yuan M; Li R; Zhang Y; Yang L; Zhang X; Tang C; Guo D
Ultrasound Med Biol; 2019 Jan; 45(1):26-34. PubMed ID: 30292461
[TBL] [Abstract][Full Text] [Related]
32. [Analysis of strong invasive clinical features and poor prognosis in macrotrabecular-massive hepatocellular carcinoma].
Shan YY; Wang CN; Mao SQ; Yu X; Sun JN; Lu CD
Zhonghua Gan Zang Bing Za Zhi; 2023 Dec; 31(12):1318-1325. PubMed ID: 38253077
[No Abstract] [Full Text] [Related]
33. Preoperative differentiation of hepatocellular carcinoma with peripheral rim-like enhancement from intrahepatic mass-forming cholangiocarcinoma on contrast-enhanced MRI.
Zhang S; Huo L; Feng Y; Zhang J; Wu Y; Liu Y; Lu L; Jia N; Liu W
Front Oncol; 2022; 12():986713. PubMed ID: 36505850
[TBL] [Abstract][Full Text] [Related]
34. Value of α-fetoprotein in association with clinicopathological features of hepatocellular carcinoma.
Liu C; Xiao GQ; Yan LN; Li B; Jiang L; Wen TF; Wang WT; Xu MQ; Yang JY
World J Gastroenterol; 2013 Mar; 19(11):1811-9. PubMed ID: 23555170
[TBL] [Abstract][Full Text] [Related]
35. Differential diagnosis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma by ultrasonography combined with multiphase enhanced computed tomography.
Tian H; Chen Y; Li X; Zhao L; Li S; Liao C; Wu Y; Zhang B
J Cancer; 2024; 15(11):3362-3369. PubMed ID: 38817871
[No Abstract] [Full Text] [Related]
36. Differentiation between cholangiocarcinoma and hepatocellular carcinoma with target sign on diffusion-weighted imaging and hepatobiliary phase gadoxetic acid-enhanced MR imaging: Classification tree analysis applying capsule and septum.
Min JH; Kim YK; Choi SY; Jeong WK; Lee WJ; Ha SY; Ahn S; Ahn HS
Eur J Radiol; 2017 Jul; 92():1-10. PubMed ID: 28624005
[TBL] [Abstract][Full Text] [Related]
37. [A comparative study of intrahepatic cholangiocarcinoma and hepatocellular carcinoma with reference to clinical features and prognosis].
Hu JY; Zhou HB; Liu WD; Zhang J; Hu HP; Liu J
Zhonghua Gan Zang Bing Za Zhi; 2019 Jul; 27(7):511-515. PubMed ID: 31357776
[No Abstract] [Full Text] [Related]
38. Imaging features of primary hepatic sarcomatoid carcinoma: Differentiation from hepatocellular carcinoma and intrahepatic cholangiocarcinoma on CT: A preliminary study.
Chen L; Ruan S; Wang P; Cheng Y; Wang Y; Tian W; Zhang H; Zhang X; Liang W
Heliyon; 2023 Mar; 9(3):e14123. PubMed ID: 36938423
[TBL] [Abstract][Full Text] [Related]
39. Differentiating combined hepatocellular and cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma using gadoxetic acid-enhanced MRI.
Hwang J; Kim YK; Park MJ; Lee MH; Kim SH; Lee WJ; Rhim HC
J Magn Reson Imaging; 2012 Oct; 36(4):881-9. PubMed ID: 22730271
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathologic features of patients with intrahepatic cholangiocarcinoma who are seropositive for alpha-fetoprotein-L3 and those with combined hepatocellular and cholangiocarcinoma.
Okuda H; Shiratori K; Yamamoto M; Takasaki K; Nakano M
J Gastroenterol Hepatol; 2006 May; 21(5):869-73. PubMed ID: 16704538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
